ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,300.33
-0.14%
Dow Jones
43,828.06
-0.20%
Gold vs US Dollar
2,648.955
0.00%
Brent Oil
74.135
0.00%
Bitcoin
103,096.95
1.67%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Alligator Bioscience Ab (0RK9)

  7. Alligator Bioscience Ab (0RK9) News

Alligator Bioscience Ab (0RK9)

Alligator Bioscience Ab
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0RK9
DateTimeSourceHeadlineSymbolCompany
01/04/202206:20PR Newswire (US)Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort CommencesLSE:0RK9Alligator Bioscience Ab
01/04/202206:19PR Newswire (US)Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort CommencesLSE:0RK9Alligator Bioscience Ab
23/03/202208:07PR Newswire (US)Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kgLSE:0RK9Alligator Bioscience Ab
23/03/202208:06PR Newswire (US)Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kgLSE:0RK9Alligator Bioscience Ab
11/02/202207:23PR Newswire (US)Alligator Bioscience AB: Year End report January-December 2021LSE:0RK9Alligator Bioscience Ab
11/02/202207:22PR Newswire (US)Alligator Bioscience AB: Year End report January-December 2021LSE:0RK9Alligator Bioscience Ab
01/02/202208:16PR Newswire (US)Alligator Bioscience Appoints Sumeet Ambarkhane MD as Chief Medical OfficerLSE:0RK9Alligator Bioscience Ab
01/02/202207:20PR Newswire (US)Alligator Bioscience Appoints Sumeet Ambarkhane MD as Chief Medical OfficerLSE:0RK9Alligator Bioscience Ab
19/01/202207:42PR Newswire (US)Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory BeattyLSE:0RK9Alligator Bioscience Ab
19/01/202207:41PR Newswire (US)Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory BeattyLSE:0RK9Alligator Bioscience Ab
18/01/202207:19PR Newswire (US)Alligator Bioscience Announces OPTIMIZE-1 Trial Update: Cohort Fully Dosed with No Adverse Effects ReportedLSE:0RK9Alligator Bioscience Ab
18/01/202207:16PR Newswire (US)Alligator Bioscience Announces OPTIMIZE-1 Trial Update: Cohort Fully Dosed with No Adverse Effects ReportedLSE:0RK9Alligator Bioscience Ab
16/12/202107:41PR Newswire (US)Alligator Bioscience Announces Trial Update and Early Readout for ATOR-1017 Confirming Biomarker, Safety & Tolerability DataLSE:0RK9Alligator Bioscience Ab
16/12/202107:39PR Newswire (US)Alligator Bioscience Announces Trial Update and Early Readout for ATOR-1017 Confirming Biomarker, Safety & Tolerability DataLSE:0RK9Alligator Bioscience Ab
15/12/202113:37PR Newswire (US)Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal Nature CommunicationLSE:0RK9Alligator Bioscience Ab
15/12/202113:36PR Newswire (US)Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal Nature CommunicationLSE:0RK9Alligator Bioscience Ab
08/11/202116:54PR Newswire (US)Alligator Bioscience Announces Commencement of Investigator Initiated Phase I Clinical Trial at Erasmus University RotterdamLSE:0RK9Alligator Bioscience Ab
08/11/202116:53PR Newswire (US)Alligator Bioscience Announces Commencement of Investigator Initiated Phase I Clinical Trial at Erasmus University RotterdamLSE:0RK9Alligator Bioscience Ab
08/11/202115:59PR Newswire (US)Bulletin from the extraordinary general meeting in Alligator Bioscience ABLSE:0RK9Alligator Bioscience Ab
08/11/202115:57PR Newswire (US)Bulletin from the extraordinary general meeting in Alligator Bioscience ABLSE:0RK9Alligator Bioscience Ab
21/10/202106:45PR Newswire (US)Alligator Bioscience AB: Interim report January-September 2021LSE:0RK9Alligator Bioscience Ab
21/10/202106:41PR Newswire (US)Alligator Bioscience AB: Interim report January-September 2021LSE:0RK9Alligator Bioscience Ab
07/10/202106:25PR Newswire (US)Notice of extraordinary general meeting in Alligator Bioscience ABLSE:0RK9Alligator Bioscience Ab
07/10/202106:23PR Newswire (US)Notice of extraordinary general meeting in Alligator Bioscience ABLSE:0RK9Alligator Bioscience Ab
02/09/202110:17PR Newswire (US)Alligator is exploring financing alternatives to support phase II studies for Mitazalimab, phase II preparations for ATOR-1017 as well as the development of other pipelineLSE:0RK9Alligator Bioscience Ab
02/09/202110:14PR Newswire (US)Alligator is exploring financing alternatives to support phase II studies for Mitazalimab, phase II preparations for ATOR-1017 as well as the development of other pipelineLSE:0RK9Alligator Bioscience Ab
02/09/202108:33PR Newswire (US)Positive Results from the Scandion Oncology and Alligator Bioscience Collaboration Further Supports Efficacy of Mitazalimab in Combination TherapyLSE:0RK9Alligator Bioscience Ab
18/08/202106:50PR Newswire (US)Alligator Bioscience announces Immuno-oncology Research Collaboration and License Agreement with Orion CorporationLSE:0RK9Alligator Bioscience Ab
18/08/202106:49PR Newswire (US)Alligator Bioscience announces Immuno-oncology Research Collaboration and License Agreement with Orion CorporationLSE:0RK9Alligator Bioscience Ab
16/08/202113:16PR Newswire (US)Alligator Bioscience Announces New Senior Director of Communications & Investor RelationsLSE:0RK9Alligator Bioscience Ab
 Showing the most relevant articles for your search:LSE:0RK9

Your Recent History

LSE
SBTX
Skinbiotherapeutics
LSE
SRSP
Sirius Petroleum
LSE
BOO
Boohoo
LSE
SCLP
Scancell
LSE
VRS
Versarien
LSE
TW.
Taylor Wimpey
LSE
ZED
Zenova
LSE
GKP
Gulf Keystone Petroleum
LSE
POS
Plexus
LSE
SRES
Sunrise Resources
LSE
SYME
Supply@me Capital
LSE
RRR
Red Rock Resources
LSE
ITV
Itv
LSE
AAZ
Anglo Asian Mining
LSE
FAB
Fusion Antibodies
LSE
BARC
Barclays
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved